| Active substance | venetoclax |
| Holder | Abbvie |
| Status | closed |
| Indication | in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ineligible for intensive chemotherapy and who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious condition. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update |
11/08/2022 |
Venclyxto®
Last updated on 10/09/2024